Latest News
Klaria Sumatriptan Alginate Film Receives Marketing Authorization
02/09/2024
We are proud to have been trusted by Klaria to partner with them on this important project. Read their full press release here
Celebrating our colleagues
29/08/2024
We are proud that over 14% of our colleagues have been with Simbec-Orion for more than 10 years, 22% have tenure of 5-10 years. Our two longest serving colleagues have been with us for more than 40 years! You can meet one of them, Deborah Evans, Clinic Manager at our Phase I Unit here. Managing Director, […]
Simbec-Orion Employees Hear from Rare Disease Advocates
01/07/2024
Our experience of nearly 30 years conducting clinical trials in patients living with a rare diseases has brought us into contact with many different patient organisations. Today we were honoured to be joined by Rick Thomson, CEO of Beacon, a UK-based non-profit organisation that is building a united rare disease community to support patient groups. […]
Is an MHRA accreditation relevant for patient studies?
24/06/2024
Our last blog post looked at what is required for a clinical trial unit to achieve an MHRA accreditation, including a commitment to the highest safety standards, comprehensive procedures and processes, and capable, experienced teams. The benefits of an MHRA Phase I accredited site, inspected and approved by regulators, remain the same for a patient […]
Simbec-Orion seminar, June 13, London: Oncology Therapeutics & Project Optimus
20/06/2024
During a half day seminar in central London, our scientific colleagues heard from members of our independent Drug Development Advisory Board on a range of topics, including how Project Optimus will affect clinical development plans and considerations for statistical design. You can catch up with some of the presentations on our webinar page.
Why should you choose an MHRA-accredited clinical unit?
12/06/2024
In our latest blog, we discuss the consideration when placing your phase I study in the UK. You may have come across CROs or Phase I Units with an MHRA Phase I accreditation – but what does this mean? The MHRA’s voluntary phase I accreditation scheme is available to organisations conducting phase I trials but […]
MHRA-inspected with no critical or major findings
07/05/2024
Our MHRA Phase I Accreditation and GCP inspection in May 2024 resulted in no critical or major findings, demonstrating that Simbec-Orion continues to be the leading, fully-comprehensive, clinical pharmacology and laboratory facility within the UK. Well done to everyone on the team! An MHRA phase I accreditation demands the highest quality clinical trials, delivered by experienced […]
